Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies
ACS Nano · 2025
DOI: 10.1021/acsnano.4c11928 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Ximu Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Lipids, Nanoparticles, Antibodies, Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Department of Education of Liaoning Province, National Natural Science Foundation of China, Shenyang Municipal Bureau of Science and Technology.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Shenyang Sunshine Pharmaceutical Co., Ltd. 3A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang 110027, China.
- Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
ORCID-Profile: Hongzhuo Liu
Förderung
- Department of Education of Liaoning Province
- National Natural Science Foundation of China
- Shenyang Municipal Bureau of Science and Technology
Zitieren
APA
Li, X., Ma, M., An, N., Yao, X., Yasen, G., Zhong, M., Jin, Z., He, Z., Wang, Y., & Liu, H. (2025). Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies. ACS Nano. https://doi.org/10.1021/acsnano.4c11928
Vancouver
Li X, Ma M, An N, Yao X, Yasen G, Zhong M, et al. Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies. ACS Nano. 2025. doi:10.1021/acsnano.4c11928
BibTeX
@article{Li2025,
author = {Li, Ximu and Ma, Mengyao and An, Ni and Yao, Xiaoxuan and Yasen, Guzailinuer and Zhong, Mingyuan and Jin, Zheng and He, Zhonggui and Wang, Yongjun and Liu, Hongzhuo},
title = {Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies},
journal = {ACS Nano},
year = {2025},
doi = {10.1021/acsnano.4c11928}
}
EUVIMED